Each gram contains: Mupirocin 20 mg.
Mupirocin ointment is indicated for the topical treatment of primary and secondary bacterial skin infections caused by Staphylococcus aureus including methicillin-resistant strains (MRSA), and group A beta-hemolytic streptococcus including Streptococcus pyogenes.
Primary skin infections: Impetigo, folliculitis, furunculosis and ecthyma.
Secondary infections: Infected dermatoses e.g., infected eczema. Infected traumatic lesions e.g., abrasions, insect bites, minor (not requiring hospitalization) wounds and burns.
Prophylaxis: Mupirocin may be used to avoid bacterial contamination of small wounds, incisions and other clean lesions, and to prevent infection of abrasions and small cuts and wounds.
Adults, children, elderly: 2-3 times a day for up to 10 days, depending on the response.
Hepatic impairment: As previously.
Renal impairment: (See Precautions).
Method of administration: Topical.
A small quantity of Mupirocin ointment should be applied to cover the affected area.
The treated area may be covered by a dressing.
Any product remaining at the end of treatment should be discarded.
Do not mix with other preparations, as there is a risk of dilution, resulting in a reduction in the antibacterial activity and potential loss of stability of the Mupirocin in the ointment.
Mupirocin ointment should not be given to patients with history of hypersensitivity to any of its constituents.
Patients with renal impairment.
This Mupirocin ointment is NOT SUITABLE for: ophthalmic use; intranasal use (in neonates or infants); use in conjunction with cannulae; at the site of central venous cannulation.
Avoid contact with eyes. If contaminated, the eyes should be thoroughly rinsed with water until the ointment residues have been removed.
Polyethylene glycol can be absorbed from open wounds and polyethylene glycol based ointments. Mupirocin ointment should not be used in conditions where absorption of large quantities of polyethylene glycol is possible, especially if there is evidence of moderate or severe renal impairment.
In the rare event of a possible sensitization reaction or severe local irritation occurring with the use of Mupirocin ointment, treatment should be discontinued.
The product should be rinsed off and appropriate alternative therapy for the infection can be established.
As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms.
Effect on ability to drive and use machines: No adverse effects on the ability to drive or operate machinery have been observed.
Use in Elderly: No restrictions unless the condition being treated could lead to absorption of polyethylene glycol and there is evidence of moderate or severe renal impairment.
Use in Pregnancy: Adequate human data on use during pregnancy are not available.
However, animal studies have not identified any risk to pregnancy or embryo-fetal development.
Use in Lactation: Adequate human data on use during lactation are not available.
If a cracked nipple is to be treated, it should be thoroughly washed prior to breast feeding.
Adverse reactions are listed as follows by system organ class and frequency. Frequencies are defined as: very common (≥1/10), common (≥1/100, <1/10), uncommon (≥1/1000, <1/100), rare (1/10000, <1/1000), very rare (<1/10000), including isolated reports.
Immune system disorders:
Very rare: Systemic allergic reactions with Mupirocin ointment.
Skin and subcutaneous tissue disorders:
Common: Burning localized to the area of application.
Uncommon: Itching, erythema, stinging and dryness localized to the area of application.
Cutaneous sensitization reactions to Mupirocin in the ointment base.
In vitro studies indicate that chloramphenicol interferes with the antibacterial action of mupirocin on RNA synthesis.
Instruction for Use/Handling: Wash hands after application.
Store at temperatures not exceeding 30°C. Keep in a dry place.
D06AX09 - mupirocin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.
Oint 20 mg/g x 5 g, 15 g.